化疗耐药非小细胞肺癌的MicroRNA表达分析及生物学途径

Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response Pub Date : 2021-01-29 DOI:10.3390/iecc2021-09206

S. Agelaki, Krystallia Gourlia, M. Markaki, C. Papadaki, K. Rounis, E. Vorrias, Elena Prokova, E. Lagoudaki, A. Koutsopoulos, I. Tsamardinos, D. Mavroudis

{"title":"化疗耐药非小细胞肺癌的MicroRNA表达分析及生物学途径","authors":"S. Agelaki, Krystallia Gourlia, M. Markaki, C. Papadaki, K. Rounis, E. Vorrias, Elena Prokova, E. Lagoudaki, A. Koutsopoulos, I. Tsamardinos, D. Mavroudis","doi":"10.3390/iecc2021-09206","DOIUrl":null,"url":null,"abstract":": Platinum-based chemotherapy (CT) is a standard treatment for lung cancer, however a variety of chemoresistance mechanisms can impair its efficacy. MicroRNAs (miRNAs) represent potential biomarkers for the prediction of treatment efficacy in non-small cell lung cancer (NSCLC). We herein used a bioinformatics approach to identify differentially expressed (DE) miRNAs associated with response to platinum-based CT in NSCLC. We identified 6 miRNAs targeting signaling molecules participating in biological pathways involved in cancer and drug resistance. In summary, we developed a 6-miRNA signature that potentially predicts the response to cisplatin in NSCLC and warrants further validation in clinical samples.","PeriodicalId":20534,"journal":{"name":"Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non- Small Cell Lung Cancer\",\"authors\":\"S. Agelaki, Krystallia Gourlia, M. Markaki, C. Papadaki, K. Rounis, E. Vorrias, Elena Prokova, E. Lagoudaki, A. Koutsopoulos, I. Tsamardinos, D. Mavroudis\",\"doi\":\"10.3390/iecc2021-09206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Platinum-based chemotherapy (CT) is a standard treatment for lung cancer, however a variety of chemoresistance mechanisms can impair its efficacy. MicroRNAs (miRNAs) represent potential biomarkers for the prediction of treatment efficacy in non-small cell lung cancer (NSCLC). We herein used a bioinformatics approach to identify differentially expressed (DE) miRNAs associated with response to platinum-based CT in NSCLC. We identified 6 miRNAs targeting signaling molecules participating in biological pathways involved in cancer and drug resistance. In summary, we developed a 6-miRNA signature that potentially predicts the response to cisplatin in NSCLC and warrants further validation in clinical samples.\",\"PeriodicalId\":20534,\"journal\":{\"name\":\"Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/iecc2021-09206\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/iecc2021-09206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

铂基化疗(CT)是肺癌的标准治疗方法，但多种化疗耐药机制会影响其疗效。MicroRNAs (miRNAs)是预测非小细胞肺癌(NSCLC)治疗效果的潜在生物标志物。本研究采用生物信息学方法鉴定与非小细胞肺癌铂基CT应答相关的差异表达(DE) mirna。我们发现了6个靶向信号分子的mirna，这些信号分子参与了癌症和耐药的生物学途径。总之，我们开发了一个6-miRNA标记，可以潜在地预测非小细胞肺癌对顺铂的反应，值得在临床样本中进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non- Small Cell Lung Cancer

: Platinum-based chemotherapy (CT) is a standard treatment for lung cancer, however a variety of chemoresistance mechanisms can impair its efficacy. MicroRNAs (miRNAs) represent potential biomarkers for the prediction of treatment efficacy in non-small cell lung cancer (NSCLC). We herein used a bioinformatics approach to identify differentially expressed (DE) miRNAs associated with response to platinum-based CT in NSCLC. We identified 6 miRNAs targeting signaling molecules participating in biological pathways involved in cancer and drug resistance. In summary, we developed a 6-miRNA signature that potentially predicts the response to cisplatin in NSCLC and warrants further validation in clinical samples.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

自引率

0.00%

发文量